|drug2502||Placebo multiple Wiki||1.00|
|drug2518||Placebo single Wiki||1.00|
|drug3622||XC7 100 mg single Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
Severe pneumoniae related to Coronavirus Disease (COVID-19), had a high in-hospital mortality; this condition are worst in subjects with acute kidney disease (AKI); conditioning increased mortality, days of assisted mechanical ventilation (AMV), increased nosocomial infections and high costs. We need many studies for determinated the risk factors for AKI in subjects with COVID-19. This study pretends identify the incidence of AKI in subjects with severe pneumoniae by COVID-19, describe the role of some biomarkers in the physiopathology of AKI-COVID-19; and determine the evolution of urinary biomarkers during hospitalization, like neutrophil gelatinase-associated lipocalin (NGAL), tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor binding protein-7 (IGFBP7), and interleukin-6 (IL-6) and the progression of viruria of Severe Acute Respiratory Syndrome (SARS) related to CoronaVirus 2 (CoV2) in subjects with or without AKI.
Description: To estimate the strength of association between the elevation of urinary levels of NGAL, TIMP-2, IGFBP7 and IL-6 and the development of AKI associated with SARS-CoV-2 pneumoniaMeasure: Urinary levels of renal biomarkers Time: Seven days
Description: Describe the incidence of AKI in critically ill patients with severe COVID-19 pneumoniaMeasure: Incidence of AKI Time: One month
Description: Estimate the strength of association of elevated urinary levels of NGAL, TIMP-2, IGFBP7 and IL-6 with mortalityMeasure: Urinary levels of renal biomarkers and mortality Time: 30 days
Description: Estimate the strength of association of elevated urinary levels of NGAL, TIMP-2, IGFBP7 and IL-6 with teh severity of the disease.Measure: Urinary levels of renal biomarkers and severity of the disease. Time: 30 days
Description: Identify possible risk factors (epidemiological, clinical, paraclinical, use of nephrotoxic agents) for the development of AKI in critically ill patients with COVID-19 pneumonia.Measure: Risk factors for AKI in severe COVID-19 Time: 30 days
Description: Compare the evolution over time of renal function markers (NGAL, TIMP-2 and IGFBP7) in patients with and without kidney injury.Measure: Evolution renal biomarkers Time: 7 days
Description: Compare the evolution over time of the SARS-CoV-2 viral load in patients with and without acute kidney injury.Measure: Evolution of viral load Time: 7 days
Description: Analyze the complement pathway in urine and compare its evolution over time in patients with and without acute kidney injury and SARS-CoV-2 infection.Measure: Evolution of complement pathway Time: seven days
Description: Analyze the metabolomic profile in urine in patients with and without acute kidney injury with SARS-CoV-2 infection.Measure: Metabolomic profile Time: 7 days
Description: Describe partial arterial oxygen concentration/inspired oxygen faction (PaO2/FiO2) ratio and radiologic evolution in patients with severe SARS COV2 pneumonia.Measure: Respiratory changes Time: 30 days
Description: Stablish the nosocomial infections in subjects with or without AKIMeasure: Nosocomial Infections Time: 30 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports